Skip to main content
. 2016 Aug 29;7(43):69436–69449. doi: 10.18632/oncotarget.11683

Figure 3. TNFSF15 up-regulates GATA3 expression, which promotes miR-29b production to silencing VEGF.

Figure 3

A. GATA3 mRNA levels in bEnd.3 cells treated with TNFSF15 at indicated concentrations. Data are mean±SD. *p < 0.05; **p < 0.01; one-way ANOVA. B. GATA3 mRNA levels in vehicle- (white) or TNFSF15-treated (black) bEnd.3 at indicated time intervals. Data are mean±SD. *p < 0.05; Student's t-test. C. Changes of GATA3 and VEGF protein levels in bEnd.3 cells following TNFSF15 treatment at indicated concentrations. Values are normalized to β-actin D. Changes of miR-29b levels in response to TNFSF15 treatment in the presence or absence of GATA3 siRNA (160 pmol/mL), determined by RT-PCR. Data are mean±SD. *p < 0.05; one-way ANOVA. E. Changes of VEGF protein levels following TNFSF15 treatment (0.3 Unit, 24 hrs) in the presence or absence of GATA3 siRNA (160 pmol /mL). F. Densitometry analysis of GATA3 and VEGF protein band intensities shown in panel E. Data are mean±SD. *p < 0.05; **p < 0.01; one-way ANOVA. Each experiment was performed three times.